Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease

Panminerva Medica

Volumn 56, Issue 2, 2014, Pages 189-193

  Abenavoli, L ^a   Luigiano, C ^b   Guzzi, P H ^a   Milic, N ^c   Morace, C ^d   Stelitano, L ^d   Consolo, P ^d   Miraglia, S ^b   Fagoonee, S ^e   Virgilio, C ^b   Luzza, F ^a   De Lorenzo, A ^f   Pellicano, R ^g  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b ARNAS Garibaldi   (Italy)

^c UNIVERSITY OF NOVI SAD   (Serbia)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

Author keywords

Adipokines; Fatty liver; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN;

ADULT; BLOOD; BODY MASS; DISEASE COURSE; ECHOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY; PROSPECTIVE STUDY;

ADIPOKINES; ADIPONECTIN; ADULT; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PROSPECTIVE STUDIES;

EID: 84908222061     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Younoussi ZM, Venkatesan C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med 2012;54:29-37.
2. Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8:S4-8.
3. Sanal MG. Nonalcoholic fatty liver disease: the concept and confusion. Minerva Gastroenterol Dietol 2011;57:419-26.
4. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Pro-biotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013;12:357-63.
5. Abenavoli L, Milic N. Dietary intervention in non-alcoholic fatty liver disease. J Acad Nutr Diet 2013;113:21.
6. Abenavoli L, Luigiano C, Larussa T, Milic N, De Lorenzo A, Stel-itano L et al. Liver steatosis in celiac disease: the open door. Minerva Gastroenterol Dietol 2013;59:89-95.
7. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-200.
8. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009;29:1431-8.
9. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;12:2708-15.
10. Gaggini M, Morelli M, Buzzigoli E, Defronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-60.
11. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:17-23.
12. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010;34:1255-64.
13. Abenavoli L. Adiponectin levels in nonalcoholic fatty liver disease. Metabolism 2011;60:e3.
14. Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dha-wan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes 2012;7:471-9.
15. Petta S, Amato MC, Di Marco V, Camma C, Pizzolanti G, Barcelona MR et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;35:238-47.
16. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Me-tab 2005;90:4503-9.
17. Korah TE, El-Sayed S, Elshafie MK, Hammoda GE, Safan MA. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol 2013;5:74-81.
18. Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobol-czyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009;54:177-82.
19. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Me-tab 2005;90:4503-9.
20. Şenateş E, Çolak Y, Yeşil A, Coşkunpinar E, Sahin Ö, Kahraman ÖT et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and non-alcoholic steatohepatitis score. Minerva Med 2012;103:369-76.
21. Manco M, Alisi A, Real JM, Equitani F, Devito R, Valenti L et al. Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. J Hepatol 2011;55:647-53.
22. Parola M, Marra F Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal 2011;15:461-83.
23. Polyzos SA, Kountouras J, Zavos C, Stergiopoulos C. Adipocy-tokines in insulin resistance and non-alcoholic fatty liver disease: the two sides of the same coin. Med Hypotheses 2010;74:1089-90.